相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 英文名:
COLO 320DM
- 库存:
大量
- 供应商:
中乔新舟
- 细胞类型:
细胞系
- 品系:
human
- 组织来源:
human
- 相关疾病:
否
- 物种来源:
human
- 免疫类型:
否
- 细胞形态:
咨询销售
- 器官来源:
human
- 运输方式:
T25瓶运输
- 年限:
5-10年
- 生长状态:
贴壁和悬浮
- 规格:
5 x 10^5 cells/vial
|
产品名称 |
COLO 320DM人结直肠腺癌细胞 |
|
货号 |
ZQ0327 |
|
产品介绍 |
Colo-320DM细胞系是一种人结直肠腺癌细胞系,建立于一名55岁白人女性的转移部位。这株细胞CEA、CSAp和结肠抗原3呈阴性。角蛋白和波形纖維蛋白呈弱阳性。该细胞系表现出独特的特征,对研究结直肠癌转移和化疗药物的作用具有重要意义。值得注意的是其高表达癌胚抗原(CEA),这是一种用于监测和诊断结直肠癌的有价值的生物标志物。 |
|
种属 |
人 |
|
性别/年龄 |
女/55岁 |
|
组织 |
结肠 |
|
疾病 |
杜克斯氏C型,结肠直肠腺癌 |
|
细胞类型 |
肿瘤细胞 |
|
形态学 |
圆形的并能折光的 |
|
生长方式 |
混合;贴壁和悬浮 |
|
倍增时间 |
大约48~72小时 |
|
培养基和添加剂 |
RPMI-1640(中乔新舟 货号:ZQ-200)+10%胎牛血清(中乔新舟 货号:ZQ0500)+1%P/S(中乔新舟 货号:CSP006) |
|
推荐完全培养基货号 |
ZM0327 |
|
生物安全等级 |
BSL-1 |
|
STR位点信息 |
Amelogenin: X CSF1PO: 11 D13S317: 11 D16S539: 11,12 D5S818: 12 D7S820: 9,12 TH01: 9 TPOX: 8,9 vWA: 15,18 Note: This cell line has historically exhibited instability at D7S820 # 9 and TH01 # 8 |
|
培养条件 |
95%空气,5%二氧化碳;37℃ |
|
抗原表达/受体表达 |
*** |
|
基因表达 |
*** |
|
保藏机构 |
ATCC; CCL-220 BCRC; 60108 ECACC; 87061205 |
|
供应限制 |
仅供科研使用 |
上海中乔新舟生物科技有限公司成立于2011年,历经十多年发展,主要专注于细胞生物学产品的研究和开发,专注于为药企、各类科研机构及CRO企业提供符合标准规范的细胞培养服务、细胞培养基、细胞检测试剂盒、细胞培养试剂,胎牛血清和细胞生物学技术服务等。
公司一直致力于为高等院校、研究机构、医院、CRO及CDMO企业提供细胞培养完整解决方案,这些产品旨在满足细胞培养的多样需求,确保实验和研究的有效进行。引用中乔新舟(ZQXZBIO)产品和服务的文献超数千篇。

产品服务
细胞资源:原代细胞、细胞株、干细胞、示踪细胞、耐药株细胞、永生化细胞等基因工程细胞。
试剂产品:胎牛血清、完全培养基(适用于原代细胞及细胞株)、无血清培养基、基础培养基、细胞转染试剂、重组因子、胰酶和双抗等等细胞培养所有实验相关产品。
技术服务:稳转株构建、原代细胞分离、特殊培养基定制服务、细胞检测等。

目前产品已经畅销国内30多个省市,与客户建立长期的合作伙伴关系,共同实现成功。全体员工将不懈努力,继续为科研人员提供优良的产品和服务,致力成为全球细胞培养领域的参与者。

企业愿景
致力于成为国内细胞培养基产业的佼佼者,生物医药领域上游原材料的优良提供商。
企业使命
成长为专业细胞系及原代细胞培养供应商、专业细胞培养基及培养试剂生产商。
企业荣誉


风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验PubMed=498117
Quinn L.A., Moore G.E., Morgan R.T., Woods L.K.
Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions.
Cancer Res. 39:4914-4924(1979)
PubMed=3164477; DOI=10.1073/pnas.85.13.4804
Von Hoff D.D., Needham-VanDevanter D.R., Yucel J., Windle B.E., Wahl G.M.
Amplified human MYC oncogenes localized to replicating submicroscopic circular DNA molecules.
Proc. Natl. Acad. Sci. U.S.A. 85:4804-4808(1988)
PubMed=7874267; DOI=10.1007/BF02349278
Ikuta S., Itoh F., Hinoda Y., Toyota M., Makiguchi Y., Imai K., Yachi A.
Expression of cytoskeletal-associated protein tyrosine phosphatase PTPH1 mRNA in human hepatocellular carcinoma.
J. Gastroenterol. 29:727-732(1994)
PubMed=7651727
Kastrinakis W.V., Ramchurren N., Rieger K.M., Hess D.T., Loda M., Steele G., Summerhayes I.C.
Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.
Oncogene 11:647-652(1995)
PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)
PubMed=16418264; DOI=10.1073/pnas.0510146103
Liu Y., Bodmer W.F.
Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006)
PubMed=18258742; DOI=10.1073/pnas.0712176105
Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.
Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.
Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008)
PubMed=19927377; DOI=10.1002/gcc.20730
Knutsen T., Padilla-Nash H.M., Wangsa D., Barenboim-Stapleton L., Camps J., McNeil N.E., Difilippantonio M.J., Ried T.
Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines.
Genes Chromosomes Cancer 49:204-223(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=20606684; DOI=10.1038/sj.bjc.6605780
Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.
5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.
Br. J. Cancer 103:340-346(2010)
PubMed=22538498; DOI=10.1159/000338793
Grozinsky-Glasberg S., Shimon I., Rubinfeld H.
The role of cell lines in the study of neuroendocrine tumors.
Neuroendocrinology 96:173-187(2012)
PubMed=23272949; DOI=10.1186/1755-8794-5-66
Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A., Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A., Orphanides G., French T., Wessels L.F.A.
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.
BMC Med. Genomics 5:66.1-66.15(2012)
PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013
Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S., O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F., Mariadason J.M., Sieber O.M.
Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.
Cancer Res. 74:3238-3247(2014)
PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)
PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)
PubMed=25926053; DOI=10.1038/ncomms8002
Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.
Nat. Commun. 6:7002.1-7002.10(2015)
PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)
PubMed=28179481; DOI=10.1158/1535-7163.MCT-16-0578
Tanaka N., Mashima T., Mizutani A., Sato A., Aoyama A., Gong B., Yoshida H., Muramatsu Y., Nakata K., Matsuura M., Katayama R., Nagayama S., Fujita N., Sugimoto Y., Seimiya H.
APC mutations as a potential biomarker for sensitivity to tankyrase inhibitors in colorectal cancer.
Mol. Cancer Ther. 16:752-762(2017)
PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)
PubMed=29101300; DOI=10.15252/msb.20177701
Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S., Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S., Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J., Weichert W., Knapp S., Feller S.M., Kuster B.
Pharmacoproteomic characterisation of human colon and rectal cancer.
Mol. Syst. Biol. 13:951-951(2017)
/LGCAdvancedCatalogueSearch/tabid/961/Default.aspx?CollectionID=106 ATCC® Number Description Designation CCL-218 Homo sapiens (human) WiDr CCL-220 Homo sapiens (human) COLO 320DM CCL-220.1 Homo sapiens (human) COLO 320HSR [COLO 320 HSR] CCL-221 Homo
人类组织肿瘤细胞 10104 人淋巴瘤细胞(B类)A-204 人横纹肌肉瘤A375 人皮肤黑色素瘤细胞A431 人皮肤基底细胞癌A549 人肺癌细胞A875 人黑色素瘤细胞BeWo 人胎盘绒毛癌细胞BGC-823 人胃腺癌细胞BT474 人乳腺导管瘤CACO-2 人结肠癌细胞CaLu-3 人肺腺癌细胞CASKI 人宫颈癌Colo205 人结肠癌Colo320DM 人结肠癌D341 Med 人髓母细胞瘤Daudi 人B淋巴细胞瘤DMF7 双位点HC-KIT
众所周知,糖化血红蛋白(HbA1c)是人体血液中红细胞内血红蛋白与血糖结合的产物,其寿命约 8~12 周,且由于不因单次血糖水平的波动而受影响,因此其能够较好反应 DM 患者过去 2~3 月血糖控制水平。目前 ADA(美国糖尿病学会)建议其控制在<7%,IDF(国际糖尿病联盟)以及我国控制标准建议 HbA1c<6.5%。 一直以来 HbA1c 都被认为是 DM 治疗监测的「金标准」,但近期,来自爱尔兰高威大学内分泌系的医学教授 DerekT.O Keeffe 等人通过临床
技术资料暂无技术资料 索取技术资料











